Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: A molecular epidemiological approach

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 428, Issue 1-2, 1999, Pages 187-196

  Sylla, Abdoulaye ^a   Diallo, Mamadou Samba ^a   Castegnaro, Jean Jacques ^b   Wild, Christopher Paul ^c  

^a Inst Rech Biol Appl Guinee I   (Guinea)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c The Medical School   (United Kingdom)

Author keywords

Adduct; Aflatoxin; Biomarker; Hepatitis B virus; Hepatocellular carcinoma; Liver

Indexed keywords

AFLATOXIN; AFLATOXIN B1; DNA FRAGMENT; HEPATITIS B VACCINE; VIRUS ENVELOPE PROTEIN;

CANCER INCIDENCE; CANCER RISK; CONFERENCE PAPER; FOOD INTAKE; GUINEA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

AFLATOXINS; ANIMALS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; COCARCINOGENESIS; EPIDEMIOLOGY, MOLECULAR; HEPATITIS B; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RISK FACTORS;

ANIMALIA; HEPATITIS B VIRUS; MUS MUSCULUS;

EID: 0032795048     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(99)00046-0     Document Type: Conference Paper

References (61)

1. Pisani P., Parkin D.M., Munoz N., Ferlay J. Cancer and Infection: Estimates of the Attributable Fraction in 1990. Cancer Epidemiol. Biomarkers Prev. 6:1997;387-400.
2. R. Montesano, C.P. Wild, Chemical-viral interactions in carcinogenesis, in: O. Iversen (Ed.), New Frontiers in Cancer Causation, Proceedings of the Second International Conference on Theories of Carcinogenesis, Taylor and Francis, Washington, 1993, pp. 283-299.
3. Wild C.P., Pisani P. Carcinogen-DNA and -protein adducts as biomarkers of human exposure in environmental cancer epidemiology. Cancer Detect. Prev. 22:1998;273-283.
4. Montesano R., Hainaut P., Wild C.P. Hepatocellular carcinoma: from gene to public health. J. Natl. Cancer Inst. 89:1997;1844-1851.
5. Ross R.K., Yuan J.-M., Yu M.C., Wogan G.N., Qian G.S., Tu J.T., Groopman J.D., Gao Y.T., Henderson B.E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet. 339:1992;943-946.
6. Qian G.S., Ross R.K., Yu M.C., Yuan J.M., Gao Y.T., Henderson B.E., Wogan G.N., Groopman J.D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 3:1994;3-10.
7. Wang L.Y., Hatch M., Chen C.J., Levin B., You S.L., Lu S.N., Wu M.H., Wu W.P., Wang L.W., Wang Q., Huang G.T., Yang P.M., Lee H.S., Santella R.M. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer. 67:1996;620-625.
8. Evans A.A., O'Connell A.P., Pugh J.C., Mason W.S., Shen F.-M., Chen G.-C., Lin W.-Y., Dia A., M'Boup S., Drame B., London W.T. Geographic variation in viral load among Hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev. 7:1998;559-565.
9. IARC Biannual Report, International Agency for Research on Cancer, Lyon, France, 1997, p. 56.
10. IARC, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 59, Hepatitis Viruses, International Agency for Research on Cancer, Lyon, 1994.
11. Wild C.P., Kleihues P. Etiology of cancer in humans and animals. Exp. Toxicol. Pathol. 48:1996;95-100.
12. Chisari F.V., Klopchin K., Moriyama T., Pasquinelli C., Dunsford H.A., Sell S., Pinkert C.A., Brinster R.L., Palmiter R.D. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell. 59:1989;1145-1156.
13. Dunsford H.A., Sell S., Chisari F.V. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis-B virus transgenic mice. Cancer Res. 50:1990;3400-3407.
14. Sell S., Hunt J.M., Dunsford H.A., Chisari F.V. Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res. 51:1991;1278-1285.
15. Lee T.H., Finegold M.J., Shen R.F., DeMayo J.L., Woo S.L.C., Butel J.S. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J. Virol. 64:1990;5939-5947.
16. Kim C.M., Koike K., Saito I., Miyamura T., Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 351:1991;317-320.
17. Feitelson M.A., Duan L.X. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am. J. Pathol. 150:1997;1141-1157.
18. 1 in the development of murine liver cancer. Int. J. Oncol. 7:1995;735-740.
19. Slagle B.L., Lee T.H., Medina D., Finegold M.J., Butel J.S. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol. Carcinog. 15:1996;261-269.
20. Chisari F.V. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology. 22:1995;1316-1325.
21. Yan R.Q., Su J.J., Huang D.R., Gan Y.C., Yang C., Huang G.H. Human hepatitis B virus and hepatocellular carcinoma: II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1. J. Cancer Res. Clin. Oncol. 122:1996;289-295.
22. Walter E., Keist R., Niederost B., Pult I., Blum H.E. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology. 24:1996;1-5.
23. Popper H., Roth L., Purcell R.H., Tennant B.C., Gerin J.L. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc. Natl. Acad. Sci. U.S.A. 84:1987;866-870.
24. Bannasch P., Khoshkhou N.I., Hacker H.J., Radaeva S., Mrozek M., Zillmann U., Kopp-Schneider A., Haberkorn U., Elgas M., Tolle T., Roggendorf M., Toshdov I. Synergistic hepatocarcinogenic effect of hepadnaviral infection and dietary aflatoxin B1 in woodchucks. Cancer Res. 55:1995;3318-3330.
25. Cullen J.M., Marion P.L., Sherman G.J., Hong X., Newbold J.E. Hepatic neoplasms in aflatoxin B1-treated, congenital duck hepatitis B virus-infected, and virus-free Peking ducks. Cancer Res. 50:1990;4072-4080.
26. Cova L., Wild C.P., Mehrotra R., Turusov V., Shirai T., Lambert V., Jacquet C., Tomatis L., Trepo C., Montesano R. Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumours in ducks. Cancer Res. 50:1990;2156-2163.
27. Uchida T., Suzuki K., Esumi M., Arii M., Shikata T. Influence of aflatoxin B1 intoxication on duck livers with duck hepatitis B virus infection. Cancer Res. 48:1988;1559-1565.
28. Duflot A., Mehrotra R., Yu S.Z., Barraud L., Trepo C., Cova L. Spectrum of liver disease and duck hepatitis B virus infection in a large series of Chinese ducks with hepatocellular carcinoma. Hepatology. 21:1995;1483-1491.
29. Harris C.C., Sun T.T. Interactive effects of chemical carcinogens and hepatitis B virus in the pathogenesis of hepatocellular carcinoma. Cancer Surv. 5:1986;765-780.
30. Wild C.P., Jansen L.A., Cova L., Montesano R. Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environ. Health Perspect. 99:1993;115-122.
31. Wild C.P., Hall A.J. Hepatitis B virus and liver cancer - unanswered questions. Cancer Surv. 33:1998;35-54.
32. De Flora S., Hietanen E., Bartsch H., Camoirano A., Izzotti A., Bagnasco M., Millman I. Enhanced metabolic activation of chemical hepatocarcinogens in woodchucks infected with hepatitis B virus. Carcinogenesis. 10:1989;1099-1106.
33. 1-8,9-epoxide in woodchucks undergoing chronic active hepatitis. Int. J. Cancer. 73:1997;587-591.
34. Chemin I., Takahashi S., Belloc C., Lang M.A., Ando K., Guidotti L.G., Chisari F.V., Wild C.P. Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model of fulminant-hepatitis. Hepatology. 24:1996;649-656.
35. Kirby G.M., Chemin I., Montesano R., Chisari F.V., Lang M.A., Wild C.P. Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol. Carcinog. 11:1994;74-80.
36. Chomarat P., Rice J.M., Slagle B.L., Wild C.P. Hepatitis B virus-induced liver injury and altered expression of carcinogen metabolising enzymes: the role of the HBx protein. Toxicol. Lett. 102:1998;595-601.
37. Chemin I., Ohgaki H., Chisari F.V., Wild C.P. Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Liver. 19:1999;81-87.
38. Chomarat P., Sipowicz M.A., Diwan B.A., Fornwald L.W., Awasthi Y.C., Anver M.A., Rice J.M., Anderson L.M., Wild C.P. Distinct time courses of increase in cytochromes P450 1A2, 2A5 and glutathione S-transferases during the progressive hepatitis associated with Helicobacter hepaticus. Carcinogenesis. 18:1997;2179-2190.
39. Kirby G.M., Pelkonen P., Vatanasapt V., Camus A.-M., Wild C.P., Lang M.A. Association of liver fluke (Opisthorchis viverrini) infestation with increased expression of cytochrome P450 and carcinogen metabolism in male hamster liver. Mol. Carcinog. 11:1994;81-89.
40. Zhou T., Evans A.A., London W.T., Xia X., Zou H., Shen F., Clapper M.L. Glutathione S-transferase expression in hepatitis B virus-associated human hepatocellular carcinogenesis. Cancer Res. 57:1997;2749-2753.
41. Geubel A.P., Pauwels S., Buchet J.P., Dumont E., Dive C. Increased cyt P-450 dependent function in healthy HBsAg carriers. Pharmacol. Ther. 33:1987;193-196.
42. 14C -caffeine breath test Pharmacol. Toxicol. 77:1995;247-249.
43. Allen S.J., Wild C.P., Wheeler J.G., Riley E.M., Montesano R., Bennett S., Whittle H., Hall A.J., Greenwood B.M. Aflatoxin exposure, malaria and hepatitis B infection in rural Gambian children. Trans. R. Soc. Trop. Med. Hyg. 86:1992;426-430.
44. Wild C.P., Fortuin M., Donato F., Whittle H.C., Hall A.J., Wolf C.R., Montesano R. Aflatoxin, liver enzymes and hepatitis B virus infection in Gambian children. Cancer Epidemiol. Biomarkers Prev. 2:1993;555-561.
45. Wild C.P., Hudson G.J., Sabbioni G., Chapot B., Hall A.J., Wogan G.N., Whittle H., Montesano R., Groopman J.D. Dietary intake of aflatoxins and the level of albumin bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol. Biomarkers Prev. 1:1992;229.
46. Diallo M.S., Sylla A., Sidibe K., Sylla B.S., Trepo C.R., Wild C.P. Prevalence of exposure to aflatoxin and hepatitis B and C viruses in Guinea, West Africa. Nat. Toxins. 3:1995;6-9.
47. 1-DNA adducts. Cancer Epidemiol. Biomarkers Prev. 5:1996;613-619.
48. 1-DNA adducts in healthy males. Carcinogenesis. 18:1997;1189-1194.
49. Fortuin M., Chotard J., Jack A.D., Maine N.P., Mendy M., Hall A.J., Inskip H.M., George M.O., Whittle H.C. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet. 341:1993;1129-1131.
50. The Gambia Hepatitis Study Group, Hall A.J., Inskip H.M., Loik F., Chotard J., Jawara M., Vall Mayans M.et al. Hepatitis B vaccine in the expanded programme of immunisation: the Gambian experience. Lancet. 1:1989;1057-1059.
51. Hall A.J., Robertson R.L., Crivelli P.E., Lowe Y., Inskip H., Snow S.K., Whittle H. Cost-effectiveness of hepatitis B vaccine in the Gambia. Trans. R. Soc. Trop. Med. Hyg. 87:1993;333-336.
52. Chang M.H., Chen C.J., Lai M.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. 336:1997;1855-1859.
53. Kane M. Global programme for control of hepatitis B infection. Vaccine. 13:1995;S47-S49. suppl. 1.
54. C.P. Wild, F.N. Rasheed, M.F. Jawla, A.J. Hall, L.A. Jansen, R. Montesano, In-utero exposure to aflatoxin in west Africa [letter], Lancet (1991) 337-1602.
55. Some naturally occuring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins, IARC Monogr. Eval. Carcinog. Risks Hum., Vol. 56, Lyon France, 1996.
56. IPCS WHO Food Aditives Series 40, Safety Evaluation of Certain Food Additives and Contaminants. Aflatoxins, IPCS, WHO, Geneva, pp. 361-468.
57. Kensler T.W., He X., Otieno M., Egner P.A., Jacobson L.P., Chen B., Wang J.-S., Zhu Y.-R., Zhang B.-C., Wang J.-B.et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev. 7:1998;127-134.
58. M. Koulibaly, I.S. Kabba, A. Cisse, S.B. Diallo, M.B. Diallo, N. Keita, N.D., Camara, M.S. Diallo, B.S. Sylla, D.M. Parkin, Cancer incidence in Conakry, Guinea: first results from the Cancer Registry 1992-1995, Int. J. Cancer. (1997) 7039-7045.
59. B. Chapot, C.P. Wild, ELISA for quantification of aflatoxin-albumin adducts and their application to human exposure assessment, in: M. Warhol, D. Van Velzen, G.R. Bullock (Eds.), Techniques in Diagnostic Pathology, Academic Press, San Diego CA, 1991, pp. 135-155.
60. Wild C.P., Jiang Y.-Z., Allen S.J., Jansen L.A.M., Hall A.J., Montesano R. Aflatoxin-albumin adducts in human sera from different regions of the world. Carcinogenesis. 11:1990;2271-2274.
61. Denning D.W. Aflatoxin and human disease. Adverse Drug React. Acute Poisoning Rev. 6:1987;175-209.